Logo Image
|Articles|August 1, 2022

The US Purchases 66 Million Doses of Moderna’s COVID-19 Vaccine for $1.74 Billion

The United States has agreed to purchase 66 million doses of Moderna’s bivalent COVID-19 booster candidate for $1.74 billion.

Moderna announced that the United States government has agreed to purchase 66 million doses of the company’s COVID-19 vaccine booster candidate, mRNA-1273.222, for $1.74 billion on July 29, 2022. The bivalent candidate contains the Spikvax vaccine as well as the omicron BA.4/5 strain mRNA.

According to a company press release, $1.74 billion will be awarded to Moderna following the manufacture and delivery of 66 million doses of the vaccine. The agreement includes an option for the US to purchase up to an additional 234 million doses of the COVID-19 vaccine booster.

"We are pleased to extend our successful collaboration with the [US] government," said Stéphane Bancel, CEO, Moderna, in the press release. "Moderna's mRNA platform is enabling us to rapidly create mRNA-1273.222, a bivalent vaccine that specifically targets [omicron] subvariants BA.4 and BA.5, the most prevalent variants of concern in the [US] today. We remain fully committed to leveraging our innovative technology platform to offer tailored vaccines that help protect communities against COVID-19."

In addition to mRNA-1273.222, Moderna is also developing mRNA-1273.214. This contains the BA.1 omicron strain, which WHO noted may be of benefit to the public.

Source: Moderna

Related to this article

View more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more